Addressing unmet needs in relapsed/refractory multiple myeloma: an Italian Delphi consensus on current challenges and emerging therapies - PubMed
4 hours ago
- #immunotherapy
- #Delphi consensus
- #multiple myeloma
- Relapsed/refractory multiple myeloma (RRMM) remains a major clinical challenge despite treatment advances.
- Increasing use of novel frontline therapies has led to more patients refractory to key drugs like lenalidomide and daratumumab.
- Double-refractory cases present a significant challenge with limited evidence to guide treatment choices.
- Italian experts reached consensus (90% of statements) on RRMM epidemiology, treatment patterns, and unmet needs via a Delphi process.
- Limited efficacy and safety of available second- and third-line therapies highlight substantial unmet clinical needs, especially for double-refractory patients.
- Emerging immunotherapies (e.g., belantamab mafodotin, ciltacabtagene autoleucel) offer promising potential to address treatment gaps in RRMM.